Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Bristol Myers Squibb

1. Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)  Bristol Myers Squibb
2. FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma  Oncology Nursing News
3. FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma  Cure Today
4. BMS’s Breyanzi is first CAR-T approved in US for rare lymphoma  FirstWord Pharma
5. FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy  CancerNetwork

Continue Reading